Key result
Elevated serum endothelin-1 is linked to ~50% higher in-stent restenosis risk after vertebral artery stenting.
Why the study?
The study was conducted to investigate the correlation between serum endothelin-1 and in-stent restenosis following vertebral artery stenting.
Is serum endothelin-1 level associated with in-stent restenosis following vertebral artery stenting?
Cohort (n=68)
No
Is serum endothelin-1 level associated with in-stent restenosis following vertebral artery stenting?
Serum ET-1 levels are independently associated with in-stent restenosis after vertebral artery stenting and may serve as a diagnostic biomarker.
Answers are grounded in this paper and cite their sources.
Does not support routine ET-1 testing after vertebral stenting; leaves open its role as a restenosis biomarker pending prospective validation.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
He et al. (2023) conducted a cohort in Vertebral artery stenosis (n=68). Serum endothelin-1 (ET-1) vs. Lower ET-1 levels was evaluated on In-stent restenosis (ISR) (OR 1.502, 95% CI 0.042-0.212, p=0.000). Elevated serum endothelin-1 levels were independently associated with an increased risk of in-stent restenosis after vertebral artery stenting (OR 1.502).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: